Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | UBE2M | P61081 | 10/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 10/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24251983 | 0.94 | NPC1 (0.47) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL16132861 | 0.76 | NPC1 (0.52) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL24251979 | 0.73 | SMN1; SMN2 (0.52) | NPC1RAB9AKMT2ADYRK1AALDH1A1 | |
| SCHEMBL24251906 | 0.73 | NPC1 (0.38) | NPC1RAB9AMEN1KMT2AUBE2M | |
| SCHEMBL30317939 | 0.72 | UBE2M (0.50) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL28991083 | 0.72 | UBE2M (0.50) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL10987723 | 0.71 | DYRK1A (0.55) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL34471108 | 0.71 | NPC1 (0.48) | NPC1RAB9AMEN1KMT2ADYRK1A | |
| SCHEMBL9533470 | 0.71 | KMT2A (0.77) | MEN1KMT2AUBE2MDCUN1D1ALDH1A1 | |
| SCHEMBL24445074 | 0.70 | NPC1 (0.50) | NPC1RAB9AMEN1KMT2AUBE2M |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2023-09-28 | — | — | US | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| EP-4169922-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-04-26 | — | — | EP | disclosed |
| WO-2022033532-A1 | FGFR AND MUTATION INHIBITOR THEREOF, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海和誉生物医药科技有限公司 | 2022-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230303575-A1 | FGFR AND MUTATION INHIBITOR THEREOF, PREPARATION METHOD THEREFOR AND USE THEREOF | FGFR3, FGFR1, FGFR4 | NPC1 2173/4885RAB9A 3048/4885MEN1 1023/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.